Raventos B, Abellan A, Pistillo A, Reyes C, Burn E, Duarte-Salles T. Impact of the COVID-19 pandemic on eating disorders diagnoses among adolescents and young adults in Catalonia: a population-based cohort study. Int J Eat Disord. 2023 Jan;56(1):225-34. doi: 10.1002/eat.23848
Sauchelli S, Brunstrom JM. Virtual reality exergaming improves affect during physical activity and reduces subsequent food consumption in inactive adults. Appetite. 2022 Aug 1;175:106058. doi: 10.1016/j.appet.2022.106058
Cox JS, Hinton EC, Sauchelli S, Hamilton-Shield JP, Lawrence NS, Brunstrom JM. When do children learn how to select a portion size? Appetite. 2021 Sep 1;164:105247. doi: 10.1016/j.appet.2021.105247
Sauchelli S, Whitmarsh A, Hamilton-Shield J, Rogers PJ, Brunstrom JM. Adjusting the 'gravitostat': piloting the increase in torso loading to reduce adiposity. Appetite. 2021 Feb 1;157:104944. doi: 10.1016/j.appet.2020.104944
Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Sauchelli S, Clark E, Shield J, Brunstrom J, Rogers P. Food preferences in children with insulin-induced hypoglycaemia: the development of a food preference task. Poster presented at the 42nd Meeting of the British Feeding and Drinking Group; April 2018. [abstract] Appetite. 2018 Nov 1; 130:315. doi: 10.1016/j.appet.2018.05.233
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.